Skip to main content

Table 2 Comparison of Q-plex™ technology to traditional ELISA assays

From: Simultaneous multi-analyte urinary protein assay for bladder cancer detection

  Q-plex™ array Commercial ELISA assay
  Cancer Benign Cancer Benign
IL8 (pg/ml)   
Median 127.7 2.2 100.8 144.3
(Min, Max) (0.4, 5,087.5) (0.5, 185.3) (0, 4,355.3) (0, 506.3)
Mean ± SD* 423.6 ± 931.2 14.6 ± 40.9 276.8 ± 768.9 180.0 ± 138.2
MMP9 (pg/ml)   
Median 268,688 248,730.5 2,833.2 545.3
(Min, Max) (176,103.9, 3,783,990.1) (162,655.6, 867,918.5) (0, 12,988.9) (0, 7,146)
Mean + SD 469,075.4 ± 655,960.4 320,746.6 ± 171,092.6 5,236.0 ± 4,144.5 876.5 ± 1,353.0
VEGFA (pg/ml)   
Median 12,599.4 12,677.5 143.6 19.5
(Min, Max) (2,093.3, 498,114.9) (810.1, 262,356.7) (1.1, 9,874.1) (0, 184.2)
Mean + SD 33,483.5 ± 88,403.7 20,690.5 ± 39,702.7 1061.6 ± 2132.9 36.2 ± 47.4
  1. *, p < 0.05 comparing cancer cohort to benign cohort for both Q-Plex™ Array and Commercial ELISA Assay.